Close
Achema middle east
swop processing & packaging

EC approves Boehringer-Lilly’s Jardiance for chronic heart failure

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

The European Commission (EC) has granted marketing authorisation to Boehringer Ingelheim and Eli Lilly and Company’s Jardiance (empagliflozin) to treat symptomatic chronic heart failure in adult patients.

With the latest development, Jardiance became the first treatment to be approved for use in all adult patients with symptomatic chronic heart failure.

The treatment population comprises patients across the complete left ventricular ejection fraction (LVEF) spectrum, including heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF).

Administered once a day, empagliflozin is an oral, highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2).

Furthermore, it is the first Type 2 diabetes treatment to have cardiovascular death risk reduction data in its label in various nations.

The EC based its approval on data from the Phase III EMPEROR-Preserved clinical trial that assessed 10mg empagliflozin versus placebo, both given along with the standard of care.

It enrolled a total of 5,988 adult heart failure subjects with over 40% LVEF.

According to the findings, empagliflozin showed to offer a 21% relative decline in risk for the composite primary endpoint of cardiovascular mortality or hospital admission due to heart failure.

Latest stories

Related stories

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »